3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
Since joining 3SBio in June 2007, Dr. Chen has been responsible fordeveloping long-range growth strategies and pursuing strategic businessopportunities and external alliances with biotechnology and pharmaceuticalcompanies in major markets worldwide. In addition to his existingresponsibilities, Dr. Chen will assume oversight of commercial operationsincluding commercial strategy, medical and regulatory, government affairs, andexport. He will be based in Beijing, China.
Dr. Jing Lou, CEO of 3SBio, commented, ''I am very pleased to announce thepromotion of David Chen to the position of Chief Operating Officer. Sinceassuming the role of VP of Business Development, David has quicklydemonstrated his leadership skills and has played a critical role in planningand executing our future growth strategies and partnering initiatives, helpingto establish relationships with a number of potential partners around theworld. His in-depth understanding of the Chinese pharmaceutical market placecombined with his significant operating experience with multinationalpharmaceutical companies in the US make him the ideal candidate to assume thisnewly created position. I look forward to working together with David as wehelp drive the next phase of 3SBio's growth.''
Prior to joining 3SBio, Dr. Chen, 42, held various managerial positions inthe US pharmaceutical industry, including business development, sales andmarketing, market research, new product development and R&D portfoliomanagement both with Eli Lilly and GlaxoSmithKline. Prior to his experiencein the US, Dr. Chen was a practicing orthopedic surgeon at Shanghai MedicalUniversity from 1989 to 1992. He received a medical degree from the FirstMilitary Medical University in Guangzhou, China, and earned a Masters Degreein Business Administration from the Darden School of Business at theUniversity of Virginia.
About 3SBio Inc.
3SBio Inc. is a leading, fully integrated biotechnology company focused onresearching, developing, manufacturing and marketing biopharmaceuticalproducts, primarily in China. For more information, please visit 3SBio on theweb at http://www.3sbio.com .For more information, please contact: Investor Contact: Kevin Teo, CFO 3SBio Inc. Tel: +86-24-2581-1820 Email: email@example.com Investor Relations(HK): Ruby Yim Taylor Rafferty Tel: +852-3196-3712 Email: firstname.lastname@example.org Investor Relations(US): Mahmoud Siddig Taylor Rafferty Tel: +1-212-889-4350 Email: email@example.com Media Contact: John Dooley Taylor Rafferty Tel: +1-212-889-4350 Email: firstname.lastname@example.org
SOURCE 3SBio Inc.
You May Also Like